The expression of miR-17 and miR-29a in placenta-derived exosomes in LPS-induced abortion mice model: An experimental study.
Inflammation.
Placenta
miR-29a
Exosome, miR-17
Journal
International journal of reproductive biomedicine
ISSN: 2476-4108
Titre abrégé: Int J Reprod Biomed
Pays: Iran
ID NLM: 101679102
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
28
04
2020
revised:
18
08
2020
accepted:
12
10
2020
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
The expression pattern of microRNAs in placenta-derived exosomes plays a crucial role in the regulation of immune responses and inflammation at the fetal-maternal interface. Considering the immunomodulatory properties of miR-17 and miR-29a, we determined their expression levels in placenta-derived exosomes in a lipopolysaccharide (LPS)-induced abortion mice model. A total of 14 pregnant BALB/c mice, aged 6-8 wk, were randomly divided into two groups (n = 7/each) on the gestational day 11.5. While the mice in the experimental group were treated with LPS, those in the control group were treated with Phosphate buffered saline; 5 hr after the treatment, the placental cells were isolated and cultured for 48 hr. Then, the cell culture supernatants were collected and used for isolation of exosomes. The isolated exosomes were confirmed by western blot and scanning electron microscopy. The miRNAs were then extracted from exosomes, and cDNA synthesized. The expression levels of miR-17 and miR-29a were evaluated by quantitative real-time PCR analysis. Our results showed that the expression levels of miR-29a in placenta-derived exosomes obtained from the experimental group increased significantly compared to the control group. Also, the expression levels of miR-17 in the placenta-derived exosomes obtained from the experimental group were found to decrease; however, it did not show significant changes compared with the control group (p > 0.05). Inflammatory reactions at the fetal-maternal interface can alter miRNAs expression patterns in placenta-derived exosomes, especially miRNAs with immunomodulatory effects such as miR-29a.
Sections du résumé
BACKGROUND
BACKGROUND
The expression pattern of microRNAs in placenta-derived exosomes plays a crucial role in the regulation of immune responses and inflammation at the fetal-maternal interface.
OBJECTIVE
OBJECTIVE
Considering the immunomodulatory properties of miR-17 and miR-29a, we determined their expression levels in placenta-derived exosomes in a lipopolysaccharide (LPS)-induced abortion mice model.
MATERIALS AND METHODS
METHODS
A total of 14 pregnant BALB/c mice, aged 6-8 wk, were randomly divided into two groups (n = 7/each) on the gestational day 11.5. While the mice in the experimental group were treated with LPS, those in the control group were treated with Phosphate buffered saline; 5 hr after the treatment, the placental cells were isolated and cultured for 48 hr. Then, the cell culture supernatants were collected and used for isolation of exosomes. The isolated exosomes were confirmed by western blot and scanning electron microscopy. The miRNAs were then extracted from exosomes, and cDNA synthesized. The expression levels of miR-17 and miR-29a were evaluated by quantitative real-time PCR analysis.
RESULTS
RESULTS
Our results showed that the expression levels of miR-29a in placenta-derived exosomes obtained from the experimental group increased significantly compared to the control group. Also, the expression levels of miR-17 in the placenta-derived exosomes obtained from the experimental group were found to decrease; however, it did not show significant changes compared with the control group (p > 0.05).
CONCLUSION
CONCLUSIONS
Inflammatory reactions at the fetal-maternal interface can alter miRNAs expression patterns in placenta-derived exosomes, especially miRNAs with immunomodulatory effects such as miR-29a.
Identifiants
pubmed: 34278196
doi: 10.18502/ijrm.v19i5.9252
pmc: PMC8261093
doi:
Types de publication
Journal Article
Langues
eng
Pagination
433-440Informations de copyright
Copyright © 2021 Jalilvand et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing or conflicting interests.
Références
J Inflamm Res. 2012;5:67-75
pubmed: 22924006
Mol Med Rep. 2016 Mar;13(3):2351-8
pubmed: 26847841
Blood. 2011 Nov 17;118(20):5487-97
pubmed: 21972292
Nat Commun. 2015 Jun 18;6:7321
pubmed: 26084661
Immunopharmacol Immunotoxicol. 2018 Aug;40(4):333-337
pubmed: 30003821
Am J Obstet Gynecol. 2015 Oct;213(4 Suppl):S173-81
pubmed: 26428497
Cancer Manag Res. 2018 Nov 05;10:5373-5381
pubmed: 30464633
Stem Cells Int. 2017;2017:5738371
pubmed: 29348758
J Biol Chem. 2014 May 2;289(18):12446-56
pubmed: 24644282
J Extracell Vesicles. 2015 Jul 17;4:27031
pubmed: 26194179
Placenta. 2014 Feb;35 Suppl:S69-73
pubmed: 24280233
J Physiol Biochem. 2018 Nov;74(4):559-568
pubmed: 29560554
Placenta. 2016 Oct;46:1-10
pubmed: 27697215
APMIS. 2005 Apr;113(4):233-45
pubmed: 15865604
Cell Mol Immunol. 2011 Sep;8(5):388-403
pubmed: 21822296
World J Methodol. 2013 Mar 26;3(1):11-8
pubmed: 25237619
Am J Physiol Lung Cell Mol Physiol. 2017 Jan 1;312(1):L110-L121
pubmed: 27881406
J Immunol. 2012 Jan 1;188(1):454-61
pubmed: 22105995
Cell Mol Life Sci. 2018 Jan;75(2):193-208
pubmed: 28733901
Clin Exp Reprod Med. 2016 Mar;43(1):15-25
pubmed: 27104153
J Reprod Immunol. 2016 Apr;114:10-7
pubmed: 26852388
Cancer Res. 2011 Aug 15;71(16):5467-76
pubmed: 21730023
Curr Opin Pharmacol. 2009 Aug;9(4):514-20
pubmed: 19525145
BMC Cancer. 2017 Nov 09;17(1):730
pubmed: 29121858
J Transl Med. 2018 Jul 4;16(1):186
pubmed: 29973278
Exp Cell Res. 2017 Nov 15;360(2):74-80
pubmed: 28811129